ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are naturally produced by the body's immune system to help fight infections. ARX788 consists of antibodies that have been attached to a toxin that has the potential to kill cancer cells. ARX788 sticks to a protein called human epidermal growth factor receptor (HER2), which is found on some breast cancer c

Trial Details

NCT ID
NCT06224673
Phase
PHASE2
Sponsor
Laura Huppert, MD, BA
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • ARX788
  • Computed Tomography (CT)
  • Biospecimen Collection
  • Amiloride
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Male or female participants age 18 years or greater with ability to provide written informed consent for the study.
  • Eastern Cooperative Oncology Group (ECOG) score of 0-2.
  • Estimated life expectancy of at least at 6 months per investigator assessment.
  • Ability to understand and the willingness to sign a written informed consent document.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →